SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLANewsfile Corp • 08/13/22
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety QuestionedInvestors Business Daily • 08/04/22
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/04/22
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 08/04/22
Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But SurelySeeking Alpha • 07/30/22
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company UpdatesGlobeNewsWire • 07/27/22
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single DosePRNewsWire • 06/24/22
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022GlobeNewsWire • 06/08/22
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/05/22
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia's Precision Genome Engineering ConferenceGlobeNewsWire • 05/02/22